Threshold Pharmaceuticals Initiates Phase 1 Clinical Trial Evaluating TH-302 in Patients With Solid Tumors

Threshold Pharmaceuticals Initiates Phase 1 Clinical Trial Evaluating TH-302 in Patients With Solid Tumors: "REDWOOD CITY, Calif., July 26 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that it has initiated a Phase 1 clinical trial evaluating the safety of TH-302, the Company's first hypoxia-activated prodrug (HAP), in patients with advanced solid tumors."